



Sinopharm Tech Holdings Limited
國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 8156)

29 December 2023

To the Shareholders,

Election of Means of Receipt of Corporate Communications

Pursuant to the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the articles of association of Sinopharm Tech Holdings Limited (the “**Company**”), the Company is making available the following options for you to elect means of receipt of future corporate communications of the Company (the “**Corporate Communication(s)**”), which refer to any document(s) issued or to be issued by the Company for the information or action of holders of any of the Company’s securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) notice of meeting; (d) listing document; (e) circular; and (f) proxy form, in the following manners:

Option 1: to access all future Corporate Communications by electronic means through the Stock Exchange’s website at www.hkexnews.hk and the Company’s website at www.sinopharmtech.com.hk (the “**Website Version**”) instead of receiving printed copies, provided that for all Actionable Corporate Communications* and the notifications thereof, the same will be sent to you individually by email; or

Option 2: to receive both the printed English and Chinese versions of all future Corporate Communications for one year.

To support environmental protection and enhance efficient communication with you, the Company encourages and recommends that you select Option 1 above to receive the Website Version of all future Corporate Communications. To make your election, please complete the enclosed reply form (the “**Reply Form**”) in accordance with the instructions printed thereon and sign and return it by mail or by hand to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong. Please use your own envelope stuck with stamp to return the Reply Form to the Company. You may also send email with a scanned copy of the duly completed and signed Reply Form to groupadmin@sinopharmtech.com.hk.

If you elect to receive the Website Version of future Corporate Communications, you are requested to provide an email address in the Reply Form for the purpose of receiving all future Actionable Corporate Communications* and the notifications thereof in electronic form from the Company. It is your responsibility to provide an email address that is valid and functional. If no valid and functional email address is provided by you, the Company will send you by post all future Actionable Corporate Communications* and the notifications thereof in printed form, until such time when you have provided a valid and functional email address to the Company for receiving the same.

If the Company does not receive the duly completed and signed Reply Form or any response in writing indicating any objection from you by 26 January 2024, and until you inform the Company by reasonable prior notice in writing to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong or by email to groupadmin@sinopharmtech.com.hk, you are deemed to have consented to receive the Website Version of all future Corporate Communications.

You are entitled at any time by reasonable prior notice in writing to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong or by email to groupadmin@sinopharmtech.com.hk to change your choice of means of receipt of future Corporate Communications. Even if you have chosen (or are deemed to have consented) to receive the Website Version of future Corporate Communications but for any reason have difficulty in receiving or gaining access to the Website Version of the Corporate Communications, the Company will, upon your request in writing or by email to groupadmin@sinopharmtech.com.hk, send the printed form of the Corporate Communications to you free of charge.

* “*Actionable Corporate Communication(s)*” refer to any Corporate Communication from the Company that seeks instructions from its securities holders on how they wish to exercise their rights or make an election as the securities holders of the Company.

Yours faithfully,
For and on behalf of the board of
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

REPLY FORM (Notes 1-6)

To: **Sinopharm Tech Holdings Limited**
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)
Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre OR Email to: groupadmin@sinopharmtech.com.hk
11 Duddell Street, Central, Hong Kong

I/We would like to receive all future Corporate Communications (Note 7) of the Company in the manner as indicated below: (Please mark a “✓” in ONLY ONE of the following boxes.)

by electronic means through the Stock Exchange’s website at www.hkexnews.hk and the Company’s website at www.sinopharmtech.com.hk (the “Website Version”) instead of printed copies, provided that for all Actionable Corporate Communications (Note 8) and the notifications thereof, the same should be sent to my/our email address (Note 9) as below: OR

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

to receive both the **printed English and Chinese** versions for one year.

Signature: _____

Full name: _____ (English) _____ (Chinese)

Contact telephone number: _____ Date: _____

- Notes:*
1. Please complete all your details clearly. Any Reply Form that has not been completed clearly or otherwise incorrectly completed will be void at the discretion of the Company.
 2. If your shares are held in joint names, the Shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Reply Form in order to be valid.
 3. By selecting to receive the Website Version of the Corporate Communications instead of receiving printed copies, you have expressly consented to waive the right to receive the Corporate Communications in printed form.
 4. If the Company does not receive the duly completed and signed Reply Form or any response in writing indicating any objection from you by 26 January 2024, you are deemed to have consented to receive the Website Version of all future Corporate Communications.
 5. You are entitled at any time by reasonable prior notice in writing to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong or by email to groupadmin@sinopharmtech.com.hk to change your choice of means of receipt of future Corporate Communications.
 6. For the avoidance of doubt, the Company does not accept any special instructions written on this Reply Form.
 7. Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of the Company’s securities, including but not limited to: (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) notice of meeting; (d) listing document; (e) circular; and (f) proxy form.
 8. “Actionable Corporate Communication(s)” refer to any Corporate Communication from the Company that seeks instructions from its securities holders on how they wish to exercise their rights or make an election as the securities holders of the Company.
 9. If you do not provide your email address or provide an invalid or non-functional email address, all future Actionable Corporate Communication(s) and the notifications thereof in printed form will be sent to you by post at your address as appearing on the register of members maintained by our Hong Kong branch share registrar or at any other address you have provided to us for such purpose.

PERSONAL INFORMATION COLLECTION STATEMENT

- (i) “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (the “PDPO”).
- (ii) Your supply of Personal Data to the Company is on a voluntary basis. If you fail to provide sufficient information, the Company may not be able to process your instructions.
- (iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, its branch share registrar in Hong Kong, and/or other companies or bodies for any of the stated purposes, and retained for such period as may be necessary for our verification and record purposes.
- (iv) You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing to the Company (the address stated in note 5 above).

(Please cut along the dotted line 請沿虛線剪下)



Mailing Address 郵寄地址

<p>Sinopharm Tech Holdings Limited 國藥科技股份有限公司 Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong 香港中環都爹利街11號律敦治中心 律敦治大廈18樓1802室</p>
--

Please use **your own envelope stuck with stamp** to return the Reply Form to us.
當閣下寄回此回條時，請**自備信封，並貼上郵票郵寄。**